November 23, 2020 – The China National Medical Products Administration has approved denosumab for the prevention of skeletal-related events in patients with bone metastases from solid tumors and in those with multiple myeloma.
The database of the phase 1/2 trial of EO2401 in combination with nivolumab with or without bevacizumab in recurrent glioblastoma has locked.
In case you missed any, below is a recap of every episode of OncLive On Air that aired in March 2024.
The current health care economy has driven many employers to self-funding models to offer affordable health care coverage to employees.
In case you missed it, these were the key regulatory decisions made by the FDA in March 2024.
Dana M. Chase, MD, FACOG, discusses the antibody-drug conjugate tisotumab vedotin including its mechanism of action, its accelerated approval for patients with recurrent cervical cancer…
In his discussion of the CHECKMATE 8HW trial, Dr. Tanios Bekaii-Saab examined the efficacy of chemotherapy versus nivolumab plus ipilimumab as the initial treatment for…
Sundar Jagannath, MBBS, discusses linvoseltamab and expands on key efficacy and safety findings from the LINKER-MM1 trial in patients with relapsed/refractory multiple myeloma.
A survey of cancer survivors found that over a quarter had a physical disability impairing mobility and almost 10% had a disability affecting self-care.
Kenneth C. Anderson, MD, discusses the recent ODAC decisions for ide-cel and cilta-cel, highlighting clinical trial data supporting the indications.
Drs Camidge and Su discuss the aspects of medicine that strengthened Dr Su’s interest in oncology and the details of delivering lung cancer care in…
